1. Market Research
  2. > Healthcare Market Trends

Physician Views: How do European cardiologists perceive oral anticoagulants versus warfarin? – Is Eliquis, Pradaxa or Xarelto their favoured option?

  • September 2013
  • Firstword Pharma
Report ID: 1623965

Summary

Table of Contents

Sales forecasts for Bristol-Myers Squibb and Pfizer's anticoagulant product Eliquis have declined notably in recent months. According to Bloomberg, current consensus estimates suggest 2018 global revenues of $2.3 billion. This compares to a previous estimate of $3.8 billion as recently as April and expectations of over $5 billion last year prior to the drug gaining full regulatory approval.

On paper, Eliquis has the strongest clinical profile among the new generation of oral anticoagulants, argue numerous analysts and key opinion leaders (KOLs), however, this has yet to translate into commercial performance since launch. Furthermore, Bayer and Johnson & Johnson's Xarelto has continued to see its revenue performance improve robustly in recent quarters, adding further pressure on expectations for Eliquis.

When FirstWord polled US-based cardiologists in June about their usage of Eliquis, feedback suggested that superiority over Xarelto and Boehringer Ingelheim's Pradaxa was not a widely held view FirstWord Pharma PLUS subscribers can view the results and analysis from this poll here.

This may change as experience with the product increases, while both Bristol-Myers Squibb and Pfizer have argued that formulary positioning – which they expect to improve over the remainder of 2013 – and direct-to-consumer (DTC) advertising should drive an inflection in sales for Eliquis.

In Europe, the market for next-generation oral anticoagulants continues to expand robustly, noted analysts at Barclay's recently, but Eliquis – against their expectations – is failing to assume the levels of market share anticipated. This could benefit Xarelto significantly, they suggest, given that the market for these products is expected to double over the next 12 months.

This week's FirstWord Physician Views poll will ask:

• How do the clinical profiles of oral anticoagulants compare with warfarin?
• How does the clinical profile of Eliquis compare to other oral anticoagulants?
• Which product – Eliquis, Pradaxa or Xarelto – is their favoured treatment option?
• For what reason did they select that product?
• In what percentage of atrial fibrillation patients do they expect to be prescribing Eliquis to in 18 month's time?

Get Industry Insights. Simply.

  • Latest reports & slideshows with insights from top research analysts
  • 60 Million searchable statistics with tables, figures & datasets
  • More than 25,000 trusted sources
  • Single User License — provides access to the report by one individual.
  • Department License — allows you to share the report with up to 5 users
  • Site License — allows the report to be shared amongst all employees in a defined country
  • Corporate License — allows for complete access, globally.

Veronica helps you find the right report:

Testimonials

The research specialist advised us on the best content for our needs and provided a great report and follow-up, thanks very much we shall look at ReportLinker in the future.

Kate Merrick

Global Marketing Manager at
Eurotherm by Schneider Electric

We were impressed with the support that ReportLinker’s research specialists’ team provided. The report we purchased was useful and provided exactly what we want.

Category Manager at
Ikea

ReportLinker gave access to reliable and useful data while avoiding dispersing resources and spending too much time on unnecessary research.

Executive Director at
PwC Advisory

The customer service was fast, responsive, and 100% professional in all my dealings (...) If we have more research needs, I'll certainly prioritize working with ReportLinker!

Scott Griffith

Vice President Marketing at
Maurice Sporting Goods

The research specialist provided prompt, helpful instructions for accessing ReportLinker's product. He also followed up to make sure everything went smoothly and to ensure an easy transition to the next stage of my research

Jessica P Huffman

Research Associate at
American Transportation Research Institute

Excellent customer service. Very responsive and fast.

Director, Corporate Strategy at
Ingredion

I reached out to ReportLinker for a detailed market study on the Air Treatment industry. The quality of the report, the research specialist’s willingness to solve my queries exceeded my expectations. I would definitely recommend ReportLinker for in-depth industry information.

Mariana Mendoza

Global Platform Senior Manager at
Whirlpool Corporation

Thanks! I like what you've provided and will certainly come back if I need to do further research works.

Bee Hin Png

CEO at
LDR Pte Ltd

The research specialist advised us on the best content for our needs and provided a great report and follow-up, thanks very much we shall look at ReportLinker in the future.

Kate Merrick

Global Marketing Manager at
Eurotherm by Schneider Electric

Purchase Reports From Reputable Market Research Publishers

Infectious Disease Testing Market 2021: A 74-Country Analysis--Supplier Shares and Strategies, Test Volume and Sales Segment Forecasts, Technology and Instrumentation Review

  • $ 59500
  • Industry report
  • May 2017
  • by Venture Planning Group

This unique 68-country survey from VPGMarketResearch.com provides data and analysis not available from any other published source. The survey is designed to assist diagnostics industry executives, as well ...

Europe Infectious Disease Testing Market 2021: A 31-Country Analysis--Supplier Shares and Strategies, Test Volume and Sales Segment Forecasts, Technology and Instrumentation Review

  • $ 47500
  • Industry report
  • May 2017
  • by Venture Planning Group

This new report from VPGMarketResearch.com provides data and analysis not available from any other published source. The survey is designed to assist diagnostics industry executives, as well as companies ...

Hematology and Flow Cytometry Analyzers and Reagents Market 2021: A 74-Country Analysis--Supplier Shares and Strategies, Test Volume and Sales Segment Forecasts, Technology and Instrumentation Review

  • $ 47500
  • Industry report
  • May 2017
  • by Venture Planning Group

This 74-country survey from VPGMarketResearch.com provides granular data and analysis not available elsewhere. The survey is designed to help current suppliers and potential market entrants identify and ...


ref:plp2013

Reportlinker.com © Copyright 2017. All rights reserved.

ReportLinker simplifies how Analysts and Decision Makers get industry data for their business.